Please select the option that best describes you:
Topics:
Lung Cancer • Radiation Oncology • Thoracic Malignancies • Stereotactic Body Radiotherapy • Medical Oncology
For T1b or T2a NSCLC cancer, approached with SABR, should chemotherapy be considered in the adjuvant setting?
As it is suggested for larger tumors treated with surgery, based on post hoc CALGB analysis?
Answer from: Medical Oncologist at Academic Institution
It is not standard of care to give adjuvant chemotherapy in IA NSCLC.It can be considered in certain situations of stage IB, although there is no strong prospective data. The group with > 4 cm size tumars had some benefit in an unplanned subgroup analysis of the CALGB study. If other risk factors...
Sign in or Register to read more
Answer from: Radiation Oncologist at Community Practice
From the multiple phase III trials of postop adjuvant therapy for NSCLC, one could reasonably extrapolate that a policy to give chemo to all stage IB pts after SAbR does not make sense. Yes, one can consider the factors listed by @Goetz H. Kloecker such as size ≥ 4cm to select a population w...